Pulmonary Embolism - Pipeline Insight, 2021

DelveInsights, Pulmonary Embolism - Pipeline Insight, 2021, report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Pulmonary Embolism Understanding
Pulmonary Embolism: Overview
Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.

"Pulmonary Embolism - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.

Pulmonary Embolism Emerging Drugs Chapters
This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Embolism Emerging Drugs
Recombinant staphylokinase: Supergene
Recombinant staphylokinase contains forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.

Recombinant human prourokinase: Tasly Pharmaceuticals
Recombinant human prourokinase is being developed by Tasly Pharmaceuticals, for the treatment of myocardial infarction, stroke and pulmonary embolism. Human pro-urokinase, is a single chain structure urokinase-type plasminogen activator, prepared via recombinant DNA technology. The drug is in Phase II clinical studies for the treatment of pulmonary embolism.
Further product details are provided in the report..

Pulmonary Embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pulmonary Embolism
There are approx. 5+ key companies which are developing the therapies for Pulmonary Embolism. The companies which have their Pulmonary Embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases
DelveInsights report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Pulmonary Embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.

Pulmonary Embolism Report Insights
Pulmonary Embolism Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Pulmonary Embolism Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Pulmonary Embolism drugs?
How many Pulmonary Embolism drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pulmonary Embolism and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Supergene
Servier
Daiichi Sankyo Company
Tasly Pharmaceuticals
Yuhan

Key Products
Recombinant staphylokinase
S-62798
DS 1040
Recombinant human prourokinase
YHP1906

Introduction
Executive Summary
Pulmonary Embolism: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary Embolism DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Recombinant human prourokinase: Tasly Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
YHP1906: Yuhan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Pulmonary Embolism Key Companies
Pulmonary Embolism Key Products
Pulmonary Embolism- Unmet Needs
Pulmonary Embolism- Market Drivers and Barriers
Pulmonary Embolism- Future Perspectives and Conclusion
Pulmonary Embolism Analyst Views
Appendix

List Of Tables

Table 1 Total Products for Pulmonary Embolism
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Pulmonary Embolism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available